Who to call at LAVA Therapeutics NV, and when
Fundz watches for the moments LAVA Therapeutics NV starts buying, and tells you who to reach.
- An alert the day LAVA Therapeutics NV raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at LAVA Therapeutics NV, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at LAVA Therapeutics NV. With Fundz connected, it knows.
LAVA Therapeutics NV
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
AI Executive Summary
AI-powered analysis of 8-K filing content
LAVA Therapeutics became a majority-owned subsidiary of the Buyer on November 13, 2025, upon closing of a Purchase Agreement and following an extraordinary general meeting vote. Six directors resigned from the board and four new directors were appointed, including Owen Hughes as executive director, which marks a significant change in control and governance.
Key Takeaways
The Buyer's acquisition closed on November 13, 2025, making LAVA Therapeutics a majority-owned subsidiary of the Buyer and effecting a change in control.
Stephen Hurly, Jay Backstrom, Peter Kiener, James Noble, Christy Oliger and Mary Wadlinger ceased to be directors effective at closing.
3 more takeaways
Related Filings (3)
3 more filings from LAVA Therapeutics NV in the last 90 days
Filing Overview
What This Means
LAVA Therapeutics NV filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.